Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 16 | 2024 | 11094 | 0.830 |
Why?
|
Neuroendocrine Tumors | 5 | 2024 | 659 | 0.620 |
Why?
|
Retinoblastoma-Like Protein p107 | 1 | 2017 | 70 | 0.560 |
Why?
|
Tumor Microenvironment | 5 | 2024 | 3944 | 0.520 |
Why?
|
Resorcinols | 1 | 2014 | 41 | 0.460 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2024 | 2948 | 0.440 |
Why?
|
Androgen Antagonists | 4 | 2024 | 1411 | 0.420 |
Why?
|
Carcinoma, Neuroendocrine | 3 | 2022 | 343 | 0.420 |
Why?
|
Isoxazoles | 1 | 2014 | 233 | 0.410 |
Why?
|
Neuroendocrine Cells | 2 | 2024 | 61 | 0.400 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2014 | 422 | 0.380 |
Why?
|
Taxoids | 1 | 2014 | 665 | 0.360 |
Why?
|
Adenocarcinoma | 5 | 2024 | 6359 | 0.350 |
Why?
|
Cell Line, Tumor | 18 | 2024 | 17088 | 0.340 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2024 | 5329 | 0.320 |
Why?
|
Cell Differentiation | 2 | 2024 | 11651 | 0.290 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2024 | 8621 | 0.280 |
Why?
|
Receptors, Androgen | 4 | 2021 | 1089 | 0.250 |
Why?
|
SOXB1 Transcription Factors | 2 | 2017 | 283 | 0.240 |
Why?
|
Carcinoma, Renal Cell | 5 | 2019 | 3186 | 0.240 |
Why?
|
Prostatic Intraepithelial Neoplasia | 1 | 2023 | 80 | 0.210 |
Why?
|
Antineoplastic Agents | 5 | 2023 | 13643 | 0.210 |
Why?
|
Epigenesis, Genetic | 4 | 2020 | 3824 | 0.210 |
Why?
|
Signal Transduction | 4 | 2024 | 23619 | 0.200 |
Why?
|
PTEN Phosphohydrolase | 3 | 2023 | 1117 | 0.200 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2022 | 90 | 0.190 |
Why?
|
Retinoblastoma Binding Proteins | 2 | 2023 | 101 | 0.190 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2021 | 166 | 0.180 |
Why?
|
Glutamates | 1 | 2022 | 384 | 0.180 |
Why?
|
Molecular Probes | 1 | 2022 | 309 | 0.170 |
Why?
|
Mice, SCID | 5 | 2019 | 2628 | 0.170 |
Why?
|
DNA Topoisomerases, Type II | 2 | 2017 | 121 | 0.170 |
Why?
|
Indoles | 4 | 2015 | 1834 | 0.160 |
Why?
|
Receptors, Notch | 1 | 2024 | 751 | 0.160 |
Why?
|
Urea | 1 | 2022 | 449 | 0.160 |
Why?
|
Kidney Neoplasms | 4 | 2018 | 4282 | 0.160 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2021 | 505 | 0.160 |
Why?
|
Pyrroles | 2 | 2014 | 1121 | 0.150 |
Why?
|
Angiopoietin-2 | 1 | 2019 | 186 | 0.150 |
Why?
|
Mice | 14 | 2024 | 81889 | 0.140 |
Why?
|
Antigens, Surface | 1 | 2022 | 1617 | 0.140 |
Why?
|
Lysine | 1 | 2022 | 997 | 0.140 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2018 | 2060 | 0.140 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2018 | 558 | 0.130 |
Why?
|
Histone Deacetylase 1 | 1 | 2016 | 133 | 0.130 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 326 | 0.130 |
Why?
|
Cell Lineage | 3 | 2024 | 2572 | 0.120 |
Why?
|
Phenylthiohydantoin | 1 | 2017 | 206 | 0.120 |
Why?
|
Male | 28 | 2024 | 364142 | 0.120 |
Why?
|
Transcription, Genetic | 2 | 2021 | 7609 | 0.110 |
Why?
|
Animals | 17 | 2024 | 168930 | 0.110 |
Why?
|
Oncogene Protein v-akt | 1 | 2013 | 130 | 0.110 |
Why?
|
Cisplatin | 1 | 2020 | 1655 | 0.110 |
Why?
|
DNA Methylation | 3 | 2024 | 4427 | 0.100 |
Why?
|
Indazoles | 1 | 2014 | 306 | 0.100 |
Why?
|
Neoplasm Metastasis | 3 | 2019 | 4891 | 0.100 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2023 | 1899 | 0.100 |
Why?
|
Histone Deacetylases | 1 | 2016 | 712 | 0.100 |
Why?
|
Imidazoles | 2 | 2014 | 1168 | 0.090 |
Why?
|
Neoplasms, Experimental | 1 | 2017 | 1227 | 0.090 |
Why?
|
Receptor, erbB-2 | 1 | 2021 | 2597 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2014 | 562 | 0.090 |
Why?
|
Neoplasm Staging | 3 | 2021 | 11218 | 0.090 |
Why?
|
Disease Progression | 5 | 2022 | 13640 | 0.090 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2018 | 3607 | 0.090 |
Why?
|
Nuclear Proteins | 2 | 2024 | 5795 | 0.080 |
Why?
|
Humans | 28 | 2024 | 766766 | 0.070 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2014 | 1319 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2020 | 3601 | 0.070 |
Why?
|
Cell Proliferation | 4 | 2021 | 10445 | 0.070 |
Why?
|
Medical Oncology | 1 | 2019 | 2340 | 0.070 |
Why?
|
Transplantation, Heterologous | 1 | 2014 | 2391 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 3 | 2021 | 5690 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2015 | 11872 | 0.060 |
Why?
|
Fluorescent Antibody Technique | 2 | 2022 | 2470 | 0.060 |
Why?
|
Prostate | 2 | 2023 | 1757 | 0.060 |
Why?
|
Drug Therapy, Combination | 1 | 2014 | 6307 | 0.060 |
Why?
|
Pyrazoles | 1 | 2014 | 2030 | 0.060 |
Why?
|
Disease Models, Animal | 3 | 2022 | 18330 | 0.060 |
Why?
|
Prostate-Specific Antigen | 2 | 2024 | 2463 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2014 | 3511 | 0.050 |
Why?
|
A Kinase Anchor Proteins | 1 | 2023 | 57 | 0.050 |
Why?
|
Pyridines | 1 | 2014 | 2888 | 0.050 |
Why?
|
Receptors, Kainic Acid | 1 | 2022 | 91 | 0.050 |
Why?
|
Binding Sites | 2 | 2022 | 6012 | 0.050 |
Why?
|
Cell Cycle Proteins | 2 | 2023 | 3439 | 0.050 |
Why?
|
Molecular Conformation | 1 | 2022 | 540 | 0.040 |
Why?
|
Biopsy | 2 | 2024 | 6779 | 0.040 |
Why?
|
Immunohistochemistry | 3 | 2022 | 11061 | 0.040 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2023 | 2881 | 0.040 |
Why?
|
Mutation | 3 | 2021 | 30213 | 0.040 |
Why?
|
Carbazoles | 1 | 2021 | 230 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2023 | 1716 | 0.040 |
Why?
|
Cadherins | 1 | 2023 | 902 | 0.040 |
Why?
|
Apoptosis | 1 | 2014 | 9513 | 0.040 |
Why?
|
Integrins | 1 | 2022 | 839 | 0.040 |
Why?
|
Protein Binding | 2 | 2022 | 9320 | 0.040 |
Why?
|
DNA-Binding Proteins | 1 | 2015 | 9611 | 0.040 |
Why?
|
Structure-Activity Relationship | 1 | 2022 | 3053 | 0.030 |
Why?
|
Androgens | 1 | 2024 | 1280 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6512 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 755 | 0.030 |
Why?
|
Prostatectomy | 1 | 2024 | 1786 | 0.030 |
Why?
|
Transcriptional Activation | 1 | 2021 | 1749 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2016 | 6850 | 0.030 |
Why?
|
Epigenomics | 1 | 2021 | 959 | 0.030 |
Why?
|
Molecular Imaging | 1 | 2022 | 822 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2023 | 2456 | 0.030 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2015 | 94 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2016 | 545 | 0.030 |
Why?
|
Cell Membrane | 1 | 2023 | 3641 | 0.030 |
Why?
|
Fluorescent Dyes | 1 | 2022 | 1927 | 0.030 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2016 | 856 | 0.030 |
Why?
|
Etoposide | 1 | 2015 | 638 | 0.030 |
Why?
|
Neoplastic Stem Cells | 1 | 2021 | 1351 | 0.030 |
Why?
|
Repressor Proteins | 1 | 2024 | 2978 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2020 | 9525 | 0.030 |
Why?
|
Neuroblastoma | 1 | 2021 | 1266 | 0.030 |
Why?
|
RNA Interference | 1 | 2021 | 2827 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6104 | 0.020 |
Why?
|
Piperidines | 1 | 2021 | 1663 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2024 | 2902 | 0.020 |
Why?
|
Gene Silencing | 1 | 2018 | 1504 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2016 | 1604 | 0.020 |
Why?
|
Models, Molecular | 1 | 2022 | 5386 | 0.020 |
Why?
|
Nitriles | 1 | 2017 | 981 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2839 | 0.020 |
Why?
|
Benzamides | 1 | 2017 | 1375 | 0.020 |
Why?
|
Hydroxamic Acids | 1 | 2013 | 483 | 0.020 |
Why?
|
Drug Synergism | 1 | 2014 | 1756 | 0.020 |
Why?
|
Microvessels | 1 | 2014 | 586 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2018 | 1609 | 0.020 |
Why?
|
Pyridones | 1 | 2015 | 818 | 0.020 |
Why?
|
Random Allocation | 1 | 2013 | 2394 | 0.020 |
Why?
|
Gene Expression | 1 | 2022 | 7585 | 0.020 |
Why?
|
Blotting, Western | 1 | 2016 | 5022 | 0.020 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2013 | 776 | 0.020 |
Why?
|
Quinolines | 1 | 2013 | 769 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3609 | 0.020 |
Why?
|
Prognosis | 2 | 2020 | 29948 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2020 | 2561 | 0.020 |
Why?
|
Prospective Studies | 2 | 2024 | 54871 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4652 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2016 | 22352 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2015 | 1998 | 0.020 |
Why?
|
Survival Analysis | 1 | 2019 | 10100 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6550 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2016 | 5890 | 0.020 |
Why?
|
Up-Regulation | 1 | 2015 | 4142 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12825 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 9404 | 0.020 |
Why?
|
Computational Biology | 1 | 2017 | 3564 | 0.020 |
Why?
|
Cell Movement | 1 | 2016 | 5199 | 0.010 |
Why?
|
Transcription Factors | 1 | 2023 | 12150 | 0.010 |
Why?
|
DNA Damage | 1 | 2013 | 2467 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2016 | 9547 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2024 | 65273 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2017 | 3236 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10745 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 14471 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2015 | 12791 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15416 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39309 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12806 | 0.010 |
Why?
|
Aged | 2 | 2020 | 171343 | 0.010 |
Why?
|
Cohort Studies | 1 | 2020 | 41710 | 0.010 |
Why?
|
Middle Aged | 2 | 2020 | 223257 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2020 | 59550 | 0.010 |
Why?
|
Time Factors | 1 | 2015 | 40149 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2020 | 81635 | 0.010 |
Why?
|
Adult | 1 | 2018 | 223307 | 0.000 |
Why?
|
Female | 1 | 2018 | 396520 | 0.000 |
Why?
|
Concepts
(172)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(30)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_